Miguel A. Canales

Internal Medicine
912 Wright St Ste A
Arlington, TX 76012

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications

Correction: Haemostatic changes during CART cell therapy and risk of complications.

Correction: Haemostatic changes during CART cell therapy and risk of complications.

Journal: Cancer immunology, immunotherapy : CII
Published: August 25, 2026

Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas.

Integrated Single-Cell and Spatial Multi-Omics of Clonal Precursors and Immune Niches in Germinal Center Lymphomas.

Journal: Cancers
Published: March 05, 2026

Haemostatic changes during CART cell therapy and risk of complications.

Haemostatic changes during CART cell therapy and risk of complications.

Journal: Cancer immunology, immunotherapy : CII
Published: November 06, 2025

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Immunotherapy may be preferable to chemotherapy for patients with POD24 follicular lymphoma in the second-line setting.

Journal: British journal of haematology
Published: November 03, 2025

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Impact of prior bendamustine exposure on bispecific antibody outcomes in relapsed/refractory follicular lymphoma.

Journal: Blood advances
Published: September 25, 2025

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Impact of Prior Bendamustine Exposure on Bispecific Antibody Outcomes in Relapsed/Refractory Follicular Lymphoma.

Journal: Blood advances
Published: September 25, 2025

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.

Journal: Molecular cancer
Published: September 08, 2025

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes.

Journal: Blood advances
Published: September 03, 2024

IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.

IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy.

Journal: Blood
Published: July 03, 2024

Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.

Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.

Journal: HemaSphere
Published: April 26, 2024

Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).

Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7).

Journal: Blood cancer discovery
Published: June 30, 2023

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

Journal: EClinicalMedicine
Published: April 21, 2023
Showing 1-12 of 47

Last Updated: 09/26/2026